| Species |
Mouse |
| Protein Construction |
Expressed with an N-terminal Met.
April (Arg50-Leu241)
Accession # Q9D777 |
|
| Purity |
> 95% as analyzed by SDS-PAGE
> 95% as analyzed by HPLC |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
Measured by its ability to induce cell proliferation of RPMI 8226 Cells. |
| Expression System |
E. coli |
| Apparent Molecular Weight |
~21.9 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against 20 mM acetic acid. |
| Reconstitution |
It
is recommended that this vial be briefly centrifuged prior to opening to bring
the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O up to 100 μg/ml.
|
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
A Proliferation-inducing Ligand (April)) also known as TNSF13A, Tall-2, and TRDL-1, is a member of the TNF ligand (TNFL) superfamily. April is most similar to B-cell activation factor (BAFF) with which it shares 30% sequence identity, compete for two receptors, TACI and BCMA. APRIL is expressed at low levels in lymphoid tissue and is over-expressed by a number of tumors. April has a proliferative effect on both normal and tumor cell lines in vitro and in vivo. APRIL seems to be involved in the regulation of death and proliferation of tumor cells, but there are still contradictory findings regarding its overall biological effects. |
| Synonyms |
A proliferating-inducing ligand; TNFSF13; TRDL-1 alpha |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
